See, e.g., Tim Wilsdon, Jim Attridge, Eva Fiz, & Satomi Ginoza, *Policies that Encourage Innovation in Middle-Income Countries* 8 (Oct. 2012), https://www.ifpma.org/wp-content/uploads/2012/01/CRA_Policies (“[T]he great majority of international R&D sites continue to be in the US and Europe, but the importance of China has increased dramatically . . . .”);

Preetika Rana, *Your Cancer Drugs May Soon Be Discovered in China*, Wall Street Journal (Apr. 11, 2017), https://www.wsj.com/articles/china-emerges-as-powerhouse-for-biotech-drugs-1491816607 (observing that biotech R&D investment has shifted to China, due to the inability of U.S. companies to obtain patents);